SALMON EVOLUTION ASA(OSL:SALME) stock Fundamental Analysis

Fundamental Rating

SALME gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 56 industry peers in the Food Products industry. While SALME seems to be doing ok healthwise, there are quite some concerns on its profitability. SALME is valued quite expensive, but it does show an excellent growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year SALME has reported negative net income.

In the past year SALME had a positive cash flow from operations.

In the past 5 years SALME always reported negative net income.

In the past 5 years SALME reported 4 times negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -1.49%, SALME is doing worse than 76.79% of the companies in the same industry.

SALME's Return On Equity of -2.13% is on the low side compared to the rest of the industry. SALME is outperformed by 75.00% of its industry peers.

		Industry Rank	Sector Rank
ROA	-1.49%
ROE	-2.13%
ROIC	N/A

ROA(3y)-2.76%

ROA(5y)-2.34%

ROE(3y)-3.94%

ROE(5y)-3.2%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

SALME has a better Gross Margin (63.26%) than 91.07% of its industry peers.

SALME's Gross Margin has declined in the last couple of years.

SALME does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	63.26%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-11.83%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

SALME does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for SALME has been increased compared to 1 year ago.

SALME has more shares outstanding than it did 5 years ago.

SALME has a better debt/assets ratio than last year.

2.2 Solvency

SALME has an Altman-Z score of 1.94. This is not the best score and indicates that SALME is in the grey zone with still only limited risk for bankruptcy at the moment.

SALME has a Altman-Z score (1.94) which is comparable to the rest of the industry.

SALME has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.

SALME has a Debt to Equity ratio of 0.26. This is amongst the best in the industry. SALME outperforms 83.93% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.26
Debt/FCF	N/A
Altman-Z	1.94

ROIC/WACCN/A

WACC8.02%

2.3 Liquidity

A Current Ratio of 2.03 indicates that SALME has no problem at all paying its short term obligations.

With a decent Current ratio value of 2.03, SALME is doing good in the industry, outperforming 75.00% of the companies in the same industry.

SALME has a Quick Ratio of 1.54. This is a normal value and indicates that SALME is financially healthy and should not expect problems in meeting its short term obligations.

SALME's Quick ratio of 1.54 is fine compared to the rest of the industry. SALME outperforms 78.57% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.03
Quick Ratio	1.54

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 70.27% over the past year.

Looking at the last year, SALME shows a very strong growth in Revenue. The Revenue has grown by 204.36%.

SALME shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 238.62% yearly.

EPS 1Y (TTM)70.27%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%50%

Revenue 1Y (TTM)204.36%

Revenue growth 3Y238.62%

Revenue growth 5YN/A

Sales Q2Q%67.35%

3.2 Future

SALME is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 103.27% yearly.

Based on estimates for the next years, SALME will show a very strong growth in Revenue. The Revenue will grow by 62.10% on average per year.

EPS Next Y109.36%

EPS Next 2Y74.45%

EPS Next 3Y92.99%

EPS Next 5Y103.27%

Revenue Next Year15.78%

Revenue Next 2Y30.97%

Revenue Next 3Y51.3%

Revenue Next 5Y62.1%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SALME. In the last year negative earnings were reported.

Based on the Price/Forward Earnings ratio of 587.38, the valuation of SALME can be described as expensive.

Compared to the rest of the industry, the Price/Forward Earnings ratio of SALME indicates a slightly more expensive valuation: SALME is more expensive than 76.79% of the companies listed in the same industry.

Compared to an average S&P500 Price/Forward Earnings ratio of 21.38, SALME is valued quite expensively.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	587.38

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of SALME indicates a rather expensive valuation: SALME more expensive than 85.71% of the companies listed in the same industry.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	43.57

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.

SALME's earnings are expected to grow with 92.99% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y74.45%

EPS Next 3Y92.99%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

SALME does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

SALMON EVOLUTION ASA

OSL:SALME (4/25/2025, 7:00:00 PM)

6.05

-0.1 (-1.63%)

Chartmill FA Rating

GICS SectorConsumer Staples

GICS IndustryGroupFood, Beverage & Tobacco

GICS IndustryFood Products

Earnings (Last)02-11 2025-02-11/bmo

Earnings (Next)05-13 2025-05-13

Inst Owners22.26%

Inst Owner ChangeN/A

Ins Owners1.08%

Ins Owner ChangeN/A

Market Cap2.80B

Analysts85

Price Target9.63 (59.17%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-629.5%

Min EPS beat(2)-1265.05%

Max EPS beat(2)6.04%

EPS beat(4)2

Avg EPS beat(4)-311.86%

Min EPS beat(4)-1265.05%

Max EPS beat(4)100%

EPS beat(8)3

Avg EPS beat(8)-184.15%

EPS beat(12)7

Avg EPS beat(12)-108.13%

EPS beat(16)10

Avg EPS beat(16)-83.74%

Revenue beat(2)1

Avg Revenue beat(2)-15.95%

Min Revenue beat(2)-33.87%

Max Revenue beat(2)1.98%

Revenue beat(4)2

Avg Revenue beat(4)-9.66%

Min Revenue beat(4)-33.87%

Max Revenue beat(4)4.66%

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-3.32%

PT rev (3m)-2.94%

EPS NQ rev (1m)-99.94%

EPS NQ rev (3m)N/A

EPS NY rev (1m)-80.56%

EPS NY rev (3m)-94.44%

Revenue NQ rev (1m)-15.13%

Revenue NQ rev (3m)-24.89%

Revenue NY rev (1m)-4.61%

Revenue NY rev (3m)-5.35%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	587.38
P/S	6
P/FCF	N/A
P/OCF	64.59
P/B	1.26
P/tB	1.31
EV/EBITDA	43.57

EPS(TTM)-0.11

EYN/A

EPS(NY)0.01

Fwd EY0.17%

FCF(TTM)-0.71

FCFYN/A

OCF(TTM)0.09

OCFY1.55%

SpS1.01

BVpS4.81

TBVpS4.62

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-1.49%
ROE	-2.13%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	63.26%
FCFM	N/A

ROA(3y)-2.76%

ROA(5y)-2.34%

ROE(3y)-3.94%

ROE(5y)-3.2%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-11.83%

GM growth 5YN/A

F-Score5

Asset Turnover0.15

Health

		Industry Rank	Sector Rank
Debt/Equity	0.26
Debt/FCF	N/A
Debt/EBITDA	8.1
Cap/Depr	486.93%
Cap/Sales	79.5%
Interest Coverage	N/A
Cash Conversion	60.67%
Profit Quality	N/A
Current Ratio	2.03
Quick Ratio	1.54
Altman-Z	1.94

F-Score5

WACC8.02%

ROIC/WACCN/A

Cap/Depr(3y)4495.02%

Cap/Depr(5y)15899.7%

Cap/Sales(3y)642.51%

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)70.27%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%50%

EPS Next Y109.36%

EPS Next 2Y74.45%

EPS Next 3Y92.99%

EPS Next 5Y103.27%

Revenue 1Y (TTM)204.36%

Revenue growth 3Y238.62%

Revenue growth 5YN/A

Sales Q2Q%67.35%

Revenue Next Year15.78%

Revenue Next 2Y30.97%

Revenue Next 3Y51.3%

Revenue Next 5Y62.1%

EBIT growth 1Y96.38%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year118474%

EBIT Next 3Y1597.07%

EBIT Next 5Y591.36%

FCF growth 1Y19.62%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y134.82%

OCF growth 3YN/A

OCF growth 5YN/A

SALMON EVOLUTION ASA (SALME.OL) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens